Trusted Resources: Education
Scientific literature and patient education texts
Increasing Rate of Hospital Admissions in Patients with Amyloidosis (From the National Inpatient Sample)
source: The American Journal of Cardiology
year: 2019
authors: Sperry BW, Saeed IM, Raza S, Kennedy KF, Hanna M, Spertus JA
summary/abstract:Cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved or mildly reduced ejection fraction with emerging treatment options. We sought to analyze the temporal trends and impact of hospital admissions in patients with amyloidosis. The National Inpatient Sample was queried to identify patients from 2005 to 2014 who were hospitalized with a diagnosis of amyloidosis using ICD9 codes. Trends over time of prevalence, demographics, co-morbidities, and outcomes were described. Propensity-matching was used to assess the impact of amyloidosis on in-hospital outcomes, including mortality. A total of 156,914 admissions in patients with amyloidosis (age 69.86 +/− 12.33 years, 45.7% female, 68.5% Caucasian) were identified. Hospitalizations more than doubled with a peak of 21,740 per year and 62 per 100,000 admissions in 2014. Over time, patients admitted with amyloidosis were older and more likely to have co-morbid medical conditions. A diagnosis of heart failure was present in 34.7% of patients, increased over time (p = 0.001), and was associated with further morbidity and mortality.
In a propensity-matched analysis, patients admitted with amyloidosis had a longer length of stay (7.5 vs 6.2 days), were less likely to be discharged home (43.6% vs 48.7%), and were more likely to die during the hospitalization (7.4% vs 4.9%, p <0.001 for all).
DOI: 10.1016/j.amjcard.2019.08.045
read more
Related Content
-
Cardiac Amyloidosishttps://www.oneamyloidosisvoice.com/wp-c...
-
Improving Strategies for the Diagnosis of Cardiac AmyloidosisAmyloidosis refers to a group of rare bu...
-
Cardiac Amyloidosis: Pathology, Nomenclature, and TypingAmyloidosis is an increasingly recognize...
-
Treatment Update: Medications for Cardiac Amyloidosishttps://www.youtube.com/watch?v=zQAHpceU...
-
ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac AmyloidosisTreatment with the investigational drug ...
-
Pathophysiology and Treatment of Cardiac AmyloidosisAmyloid cardiomyopathy should be suspect...
-
Resurrecting Tc 99m PYP: As Cardiac Amyloidosis Therapies Emerge, an Old Test Gains a New PurposeOnce used to diagnose myocardial infarct...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.